Teclistamab manufacturer

Teclistamab (Teclistamab) is being developed by Johnson & Johnson for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including a proteasome inhibitor, an immunomodulator, and an anti-CD38 monoclonal antibody. The primary efficacy outcome measure was overall response rate (ORR), as assessed by an independent review committee using the International Myeloma Working Group 2016 criteria. ORR was 61.8% (95%confidence interval:52.1, 70.9). Median follow-up of responders was 7.4 months, and the estimated duration of response (DOR) rate at 6 months was 90.6% (95% CI: 80.3%, 95.7%) and 66.5% at 9 months (95% CI: 38.8%, 83.9%). If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.